Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F23%3AE0110414" target="_blank" >RIV/00843989:_____/23:E0110414 - isvavai.cz</a>
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/10.1111/jdv.19195" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/jdv.19195</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/jdv.19195" target="_blank" >10.1111/jdv.19195</a>

Result language
angličtina
Original language name
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial
Original language description
Atopic dermatitis (AD) is a common, chronic inflammatory skin disease characterized by itchy skin lesions. Some patients with AD present with elevated peripheral eosinophilia. Evidence suggests a role of eosinophils in the pathophysiology of AD; therefore, an eosinophil-depleting treatment, such as benralizumab, could prove beneficial, particularly in patients with increased eosinophil counts.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical
Journal of the European Academy of Dermatology and Venerology
ISSN
0926-9959
e-ISSN
1468-3083
Volume of the periodical
37
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
1
Pages from-to
e1211-e1214
UT code for WoS article
001007192600001
EID of the result in the Scopus database
2-s2.0-85163079727

Similar results(10)